SD: Specialized disclosure report
6-K: U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(4.8%)
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(5.4%)
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.7%)
TAKEDA PHARMACEUTICAL CO LTD | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Sumitomo Mitsui Trust Holdings, Inc.(5.5%)
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer (related to financial reporting)
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer (related to financial reporting)
TAKEDA PHARMACEUTICAL CO LTD | 4: Statement of changes in beneficial ownership of securities-10% Owner TAKEDA PHARMACEUTICAL CO LTD
TAKEDA PHARMACEUTICAL CO LTD | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(6.6%)
TAKEDA PHARMACEUTICAL CO LTD | SC 13G: Statement of acquisition of beneficial ownership by individuals-Takeda Pharmaceutical Company Limited(5.2%),Takeda Ventures, Inc(5.2%)
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer (related to financial reporting)
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer (related to financial reporting)
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
TAKEDA PHARMACEUTICAL CO LTD | 6-K: Report of foreign private issuer (related to financial reporting)
No Data